CAPR — Capricor Therapeutics, Inc. stock price, charts and financials

QT13Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
9.42
+0.86+10.05%
OverviewShort InterestFilings
CAPRQT13Capricor Therapeutics, Inc.·NASDAQ
9.42+10.05%
Analyst
Up 10.0% — B. Riley Securities upgraded to Buy, price target $21.
High confidence
TA
Loading chart...
Signal & projected range
Descending channel — reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MESO+3.19%$14.87FTRE+1.55%$20.28NKTR+1.45%$68.36GHRS+3.50%$28.72RAPP+1.35%$41.95AGIO+2.00%$33.61ZBIO-1.08%$31.97GPCR-1.13%$35.10
Snapshot
Index-P/E-EPS (ttm)-1.20Insider Own37.95%Shs Outstand57.51MPerf Week13.49%
Market Cap541.75MForward P/E-EPS next Y-1.49Insider Trans-1.24%Shs Float48.21MPerf Month33.05%
Enterprise Value393.75MPEG-EPS next Q-0.14Inst Own-Short Float46.01%Perf Quarter-66.30%
Income-41.00MP/S24.63EPS this Y-28.42%Inst Trans-Short Ratio3.71Perf Half Y-69.51%
Sales22.00MP/B2.20EPS next Y3.31%ROA-35.10%Short Interest22.18MPerf YTD-67.36%
Book/sh4.28P/C2.28EPS next 5Y-ROE-56.60%52W High40.38 -76.67%Perf Year51.45%
Cash/sh4.14P/FCF-EPS past 3/5Y-ROIC-40.08%52W Low2.96 218.24%Perf 3Y45.82%
Dividend Est.-EV/EBITDA0.47Sales past 3/5Y-Gross Margin0.00%Volatility7.24% 11.42%Perf 5Y88.02%
Dividend TTM-EV/Sales17.90EPS Y/Y TTM-4.35%Oper. Margin0.00%ATR (14)1.02Perf 10Y-76.97%
Dividend Ex-Date-Quick Ratio7.35Sales Y/Y TTM0.00%Profit Margin0.00%RSI (14)52.27Recom2.20
Dividend Gr. 3/5Y-Current Ratio7.35EPS Q/Q-22.81%SMA207.39%Beta0.49Target Price12.70
Payout0.00%Debt/Eq0.06Sales Q/Q-SMA50-7.91%Rel Volume0.61Prev Close8.56
Employees231LT Debt/Eq0.05EarningsNov 09SMA200-59.93%Avg Volume6.42MPrice9.42
IPO DateFeb 13, 2007Option/ShortYes / YesEPS/Sales Surpr.-18.87% -Net Debt/EBITDA0.06Volume3,931,487Change10.05%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-14-26UpgradeB. Riley SecuritiesNeutral → Buy$21
Sep-01-26UpgradePiper SandlerNeutral → Overweight$25
Aug-14-26UpgradeCantor FitzgeraldNeutral → Overweight
Jul-31-26DowngradeJones TradingBuy → Hold
Jul-30-26DowngradeCantor FitzgeraldOverweight → Neutral$3.50
Jul-30-26DowngradePiper SandlerOverweight → Neutral
Jul-30-26DowngradeHC Wainwright & Co.Buy → Neutral
Jul-28-26ReiteratedIndustrial Alliance Securities$7.00
Jul-27-26ReiteratedRoth CapitalBuy$7.00
May-15-26ReiteratedRoth CapitalBuy
Latest News· Times ET
Today
Today02:18PM
Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadlineprnewswire.com
10:30AM
Kaplan Fox Reminds Investors: Capricor Therapeutics, Inc. (CAPR) Securities Class Action Deadline is September 28, 2026newsfilecorp.com
09:05AM
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuitprnewswire.com
07:30AM
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPRglobenewswire.com
06:10AM
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Lawglobenewswire.com
06:07AM
CAPR Deadline Alert: SueWallSt Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Securities Class Action Deadline on September 28, 2026prnewswire.com
05:36AM
Faruqi & Faruqi, LLP Urges Capricor Therapeutics, Inc. (CAPR) Investors to Seek Counsel Before the September 28, 2026 Lead Plaintiff Deadline in the Securities Class Actionnewsfilecorp.com
05:21AM
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Capricor Therapeutics, Inc. (CAPR) Investors to Inquire About a Securities Fraud Class Action by September 28, 2026newsfilecorp.com
04:17AM
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)globenewswire.com
01:47AM
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadlinebusinesswire.com
Sep-16-26
Sep-16-2606:51PM
SEPTEMBER 28, 2026 CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuitprnewswire.com
12:35PM
CAPR IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPRglobenewswire.com
11:42AM
CAPR 12-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline - Hagens Bermanglobenewswire.com
10:15AM
Kaplan Fox Alerts Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery to a Securities Class Action Deadline on September 28, 2026newsfilecorp.com
08:00AM
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
Company

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue22022——————
Cost of Goods Sold Incl. D&A51050——————
Gross Profit-280-28——————
Selling, General and Administrative Excl. Other142315——————
Research and Development518450——————
Other Operating Expense-511-50——————
Operating Income-43-108-43——————
Interest Expense030——————
Unusual Expense
—————————
Non-Operating Income (Expense)262——————
Net Income Before Taxes-41-105-40——————
Income Taxes
000——————
Consolidated Net Income-41-105-40——————
Net Income From Continuing Operations-41-105-40——————
Net Income-41-105-40——————
EPS (Recurring)-1.20-2.26-1.15——————
EPS (Basic, Before Extraordinaries)-1.20-2.26-1.15——————
EPS (Diluted)-1.20-2.26-1.15——————
EBITDA-39-100-39——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio14.99—21.95——————
Gross Margin-127.27—-127.27——————
Operating Margin-195.45—-195.45——————
Net Margin-186.36—-181.82——————
Shares Outstanding354635——————
Market Capitalization3301,328483——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$40.06$29.83$19.60$9.36$-0.87● Close Price0.00M0.84M1.68M2.52M3.35MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Option Exercise3.1824,10076,63835,323Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Sale30.3824,100732,15830,547Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Sale30.3824,100732,15811,223Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Option Exercise3.1824,10076,63854,647Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Sale30.0040012,00011,223Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Option Exercise3.184001,27211,623Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Option Exercise3.184001,27230,947Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Sale30.0040012,00030,547Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 22 '26Option Exercise3.185001,59031,047Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 22 '26Option Exercise3.185001,59011,723Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 18 '26Option Exercise1.393,0004,17011,223May 19
Litvack FrankDirectorMay 13 '26Option Exercise1.393,9375,472133,776May 14
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Option Exercise3.1825,00079,50033,223May 04
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Sale31.7025,000792,5408,223May 04
Krasney KarenEVP, GENERAL COUNSELMay 01 '26Option Exercise3.1825,00079,50055,547May 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.